Editorial: Focus on malignant pleural mesothelioma immunology and immunotherapy

Chiara Porta; Didier Jean; Christophe Blanquart

doi:10.3389/fimmu.2023.1251384

Editorial: Focus on malignant pleural mesothelioma immunology and immunotherapy

Front Immunol. 2023 Jul 24:14:1251384. doi: 10.3389/fimmu.2023.1251384. eCollection 2023.

Authors

Chiara Porta^{1

2}, Didier Jean³, Christophe Blanquart^{4

5}

Affiliations

¹ Department of Pharmaceutical Sciences, University of Eastern Piedmont, Novara, Italy.
² Center for Translational Research on Autoimmune & Allergic Diseases (CAAD), University of Eastern Piedmont, Novara, Italy.
³ Centre de Recherche des Cordeliers, INSERM, Université Paris Cité, Sorbonne Université, Functional Genomics of Solid Tumors Laboratory, Paris, France.
⁴ Centre National de la Recherche Scientifique (CNRS), Paris, France.
⁵ Institut National de la Santé et de la Recherche Médicale (INSERM) U1232 Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), Nantes, France.

No abstract available

Keywords: eosinophils; immune checkpoint inhibitors; mesothelioma; microbiota; oncolytic vaccinia virus; osteopontin; predictive biomarkers; tumor microenvironment.

Publication types

Editorial

MeSH terms

Humans
Immunotherapy
Mesothelioma*
Mesothelioma, Malignant*
Pleural Neoplasms* / therapy